Holen Sie sich die Stockscreener-App
10.16
3.24%
-0.34
Schlusskurs vom Vortag:
$10.50
Offen:
$10.56
24-Stunden-Volumen:
4.16M
Relative Volume:
1.59
Marktkapitalisierung:
$1.04B
Einnahmen:
$187.64M
Nettoeinkommen (Verlust:
$-95.00M
KGV:
-10.69
EPS:
-0.95
Netto-Cashflow:
$-69.02M
1W Leistung:
+13.65%
1M Leistung:
+23.15%
6M Leistung:
+53.47%
1J Leistung:
-18.06%
1-Tages-Spanne:
$10.10
$10.90
1-Wochen-Bereich:
$10.10
$11.65
52-Wochen-Spanne:
$5.635
$13.53
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Firmenname
Day One Biopharmaceuticals Inc
Sektor
Branche
Telefon
650 484-0899
Adresse
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Vergleichen Sie DAWN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
10.16 | 1.08B | 187.64M | -95.00M | -69.02M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Fortgesetzt | TD Cowen | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-09 | Bestätigt | Needham | Buy |
| 2024-08-01 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-04-24 | Bestätigt | Needham | Buy |
| 2023-04-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-08 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-03 | Eingeleitet | Oppenheimer | Perform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Buy |
| 2022-12-01 | Eingeleitet | BofA Securities | Buy |
Alle ansehen
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
Earnings Beat: How does Day One Biopharmaceuticals Inc compare to its peersJuly 2025 Gainers & Low Volatility Stock Recommendations - baoquankhu1.vn
First Week of March 20th Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Growth Recap: How does Day One Biopharmaceuticals Inc compare to its peers2025 Earnings Impact & Daily Chart Pattern Signals - baoquankhu1.vn
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet - sharewise.com
Update Report: Is Day One Biopharmaceuticals Inc a top pick in the sectorQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Retail Trends: Can Day One Biopharmaceuticals Inc generate free cash flow2025 Big Picture & Fast Entry Momentum Alerts - baoquankhu1.vn
Rally Mode: How geopolitical tensions affect Day One Biopharmaceuticals Inc stockLayoff News & Daily Chart Pattern Signals - Bộ Nội Vụ
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 10.1%What's Next? - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains? - Nasdaq
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue And 2026 Outlook Updates - Yahoo Finance
Day One Biopharmaceuticals stock initiated with Buy rating at TD Cowen - Investing.com Canada
DAWN: OJEMDA's growth and new pipeline assets set the stage for significant revenue expansion in 2026 - TradingView — Track All Markets
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Sahm
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpTime to Buy? - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - Benzinga
Day One Biopharmaceuticals stock soars after strong 2025 revenue forecast By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Day One Biopharmaceuticals Reports 172% Year-over-Year Growth in 2025 Net Product Revenue, Projects 2026 Revenue Between $225 Million and $250 Million - Quiver Quantitative
Day One says Ojemda 2026 U.S. net product revenue projected to be $225$250 million - marketscreener.com
Oklahoma City NewsThe Oklahoman - FinancialContent
Behavioral Patterns of DAWN and Institutional Flows - Stock Traders Daily
Day One Biopharmaceuticals Stock Pre-Market (+5.4%) : Market Digests Mersana Acquisition - Trefis
How to contact the Daily Bulletin - FinancialContent
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Day One Biopharmaceuticals, Inc.Common Stock (NQ: DAWN - FinancialContent
Will Day One Biopharmaceuticals Inc. stock benefit from automationQuarterly Market Summary & Reliable Momentum Entry Alerts - ulpravda.ru
Trading Action: Is Day One Biopharmaceuticals Inc. stock a good choice for value investorsWall Street Watch & Technical Buy Zone Confirmation - Улправда
How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN) - Yahoo Finance
Day One concludes Mersana Therapeutics acquisition - Yahoo Finance
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics By Investing.com - Investing.com Australia
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Investing.com
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics - TipRanks
Day One Biopharmaceuticals Signs Contingent Value Rights Agreement With Computershare - TradingView — Track All Markets
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline - Quiver Quantitative
Day One Completes Acquisition of Mersana Therapeutics - GlobeNewswire
About Us | Laser Focus WorldDay One Completes Acquisition of Mersana Therapeutics - FinancialContent
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Index Biomarker Science - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
(DAWN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
When Can We Expect A Profit From Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)? - 富途牛牛
How The Mersana Deal Is Rewriting The Story Behind Day One Biopharmaceuticals Valuation - Yahoo Finance
Is Day One Biopharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Price-Driven Insight from (DAWN) for Rule-Based Strategy - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 6%What's Next? - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Sahm
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026I'm Bullish (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Day One Biopharmaceuticals Reports Promising FIREFLY-1 Trial Results - timothysykes.com
Finanzdaten der Day One Biopharmaceuticals Inc-Aktie (DAWN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Day One Biopharmaceuticals Inc-Aktie (DAWN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| York Charles N II | COO and CFO |
Nov 17 '25 |
Sale |
8.91 |
4,062 |
36,212 |
294,715 |
| Merendino Lauren | Chief Commercial Officer |
Nov 17 '25 |
Sale |
8.91 |
3,726 |
33,216 |
50,809 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Nov 17 '25 |
Sale |
8.91 |
15,894 |
141,690 |
177,165 |
4.73%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):